



NDA 20-154/S-040, S-041  
NDA 20-155/S-030, S-031  
NDA 20-156/S-031, S-032

Bristol-Myers Squibb  
Attention: Marie-Laure Papi  
Senior Regulatory Associate  
5 Research Parkway  
P.O. Box 5100  
Wallingford, CT 06492-7660

Dear Ms. Papi:

Please refer to your supplemental new drug applications dated May 31, 2002, received June 3, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for VIDEX® (didanosine) Buffered Tablets, VIDEX® (didanosine) Buffered Powder for Oral Solution, and VIDEX® (didanosine) Pediatric Powder.

We acknowledge receipt of your submissions dated August 30, 2002, and September 19, 2002.

These supplemental new drug applications provide for changes to the VIDEX® package insert and patient package insert that describe the potential risk of didanosine-related adverse events when VIDEX® and ribavirin are co-administered.

Please also refer to your supplemental new drug applications dated July 11, 2002, received July 12, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for VIDEX® (didanosine) Buffered Tablets, VIDEX® (didanosine) Buffered Powder for Oral Solution, and VIDEX® (didanosine) Pediatric Powder.

We acknowledge receipt of your submissions dated July 25, 2002, and September 19, 2002.

These supplemental new drug applications provide for changes to the VIDEX® package insert and patient package insert that describe the results of pharmacokinetic drug interaction studies in which significant increases in didanosine exposures were observed, and the potential risk of didanosine-related adverse events when VIDEX® and tenofovir disoproxil fumarate are co-administered.

We have completed the review of these supplemental applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the agreed upon labeling text. Accordingly, these supplemental applications are approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted September 19, 2002, patient package insert submitted September 19, 2002).

Please submit the copies of final printed labeling (FPL) electronically to each application according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplement NDA 20-154/S-040, S-041, 20-155/S-030, S-031, 20-156/S-031, S-032." Approval of these submissions by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for these products. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package inserts directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please call Destry Sullivan, M.S., Regulatory Project Manager, at (301) 827-2335.

Sincerely,

*{See appended electronic signature page}*

Debra Birnkrant, M.D.  
Director  
Division of Antiviral Drug Products  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Debra Birnkrant  
9/25/02 04:03:13 PM  
NDA 20-156 NDA 20-155, NDA 20-154